{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:03:58Z","timestamp":1789995838255,"version":"4.0.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Proteomics International"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s41669-026-00669-4","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:12:43Z","timestamp":1783707163000},"page":"897-907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic Impact of PromarkerD In Vitro Diagnostic Testing on the Management of Chronic Kidney Disease in Type 2 Diabetes: A Budget Impact Analysis"],"prefix":"10.1007","volume":"10","author":[{"given":"Gareth C.","family":"Fernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella A.","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1406-8797","authenticated-orcid":false,"given":"Kirsten E.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianzhi K.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline S.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl L.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Shanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Lipscombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"669_CR1","unstructured":"Rout P, Aslam A. End-stage renal disease. StatPearls. Treasure Island (FL): StatPearls Publishing; 2025."},{"issue":"1","key":"669_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7\u201311.","journal-title":"Kidney Int Suppl (2011)"},{"key":"669_CR3","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases NIoH. United States renal data system 2024 Annual Data Report. 2024; Available from: https:\/\/usrds-adr.niddk.nih.gov\/2024"},{"key":"669_CR4","unstructured":"Vaidya SR, Aeddula NR. Chronic kidney disease. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024."},{"issue":"20 Suppl","key":"669_CR5","first-page":"S369","volume":"27","author":"KA Betts","year":"2021","unstructured":"Betts KA, Song J, Faust E, Yang K, Du Y, Kong SX, et al. Medical costs for managing chronic kidney disease and related complications in patients with chronic kidney disease and type 2 diabetes. Am J Manag Care. 2021;27(20 Suppl):S369\u201374.","journal-title":"Am J Manag Care"},{"issue":"1","key":"669_CR6","first-page":"80","volume":"29","author":"H Chung","year":"2023","unstructured":"Chung H, Crowe CL, Kong SX, Singh R, Farej R, Elliott J, et al. Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insured population. J Manag Care Spec Pharm. 2023;29(1):80\u20139.","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"669_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20(7):473\u201385.","journal-title":"Nat Rev Nephrol"},{"key":"669_CR8","unstructured":"Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4s):S117\u2013s314."},{"issue":"2","key":"669_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1053\/j.ajkd.2024.08.003","volume":"85","author":"SD Navaneethan","year":"2025","unstructured":"Navaneethan SD, Bansal N, Cavanaugh KL, Chang A, Crowley S, Delgado C, et al. KDOQI US Commentary on the KDIGO 2024 clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2025;85(2):135\u201376.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"669_CR10","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2215\/CJN.10321014","volume":"10","author":"D Dunkler","year":"2015","unstructured":"Dunkler D, Gao P, Lee SF, Heinze G, Clase CM, Tobe S, et al. Risk prediction for early CKD in Type 2 diabetes. Clin J Am Soc Nephrol. 2015;10(8):1371\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"14","key":"669_CR11","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4239\/wjd.v7.i14.290","volume":"7","author":"CH Lin","year":"2016","unstructured":"Lin CH, Chang YC, Chuang LM. Early detection of diabetic kidney disease: present limitations and future perspectives. World J Diabetes. 2016;7(14):290\u2013301.","journal-title":"World J Diabetes"},{"issue":"5","key":"669_CR12","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1093\/jalm\/jfaf097","volume":"10","author":"JKC Lui","year":"2025","unstructured":"Lui JKC, Peters KE, Fernandez G, Joubert IA, Lumbantobing TSC, Davis TME, et al. Analytical and clinical performance of a novel immunoassay-based test system to predict diabetic kidney disease. J Appl Lab Med. 2025;10(5):1140\u201353.","journal-title":"J Appl Lab Med."},{"issue":"4","key":"669_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1177\/0091270011400604","volume":"52","author":"RK Ghosh","year":"2012","unstructured":"Ghosh RK, Ghosh SM, Chawla S, Jasdanwala SA. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol. 2012;52(4):457\u201363.","journal-title":"J Clin Pharmacol"},{"issue":"22","key":"669_CR14","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"669_CR15","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"669_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"669_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323\u201334.","journal-title":"N Engl J Med"},{"key":"669_CR18","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 11. Chronic kidney disease and risk management: standards of care in diabetes\u20142024. Diabetes Care. 2023;47(Supplement_1):S219\u2013S30.","DOI":"10.2337\/dc24-S011"},{"key":"669_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.deman.2023.100184","volume":"13","author":"AJ Scheen","year":"2024","unstructured":"Scheen AJ. Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk. Diabetes Epidemiol Manage. 2024;13:100184.","journal-title":"Diabetes Epidemiol Manage"},{"issue":"4","key":"669_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.6139","volume":"4","author":"LA Eberly","year":"2021","unstructured":"Eberly LA, Yang L, Eneanya ND, Essien U, Julien H, Nathan AS, et al. Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US. JAMA Netw Open. 2021;4(4):e216139.","journal-title":"JAMA Netw Open"},{"key":"669_CR21","unstructured":"Centers for Disease Control and Prevention. Kidney Disease Surveillance System: Percentage of adults aged \u226518 years with CKD stages 1\u20134 aware of their condition, by stage, United States. 2025; Available from: https:\/\/nccd.cdc.gov\/CKD\/detail.aspx?Qnum=Q719"},{"issue":"1","key":"669_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5\u201314.","journal-title":"Value Health"},{"key":"669_CR23","unstructured":"Centers for Disease Control and Prevention. National diabetes statistics report. 2026; Available from: https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html"},{"key":"669_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/1756-0500-7-415","volume":"7","author":"RA Bailey","year":"2014","unstructured":"Bailey RA, Wang Y, Zhu V, Rupnow MF. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes. 2014;7:415.","journal-title":"BMC Res Notes"},{"issue":"1","key":"669_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12882-020-01792-y","volume":"21","author":"GA Nichols","year":"2020","unstructured":"Nichols GA, D\u00e9ruaz-Luyet A, Brodovicz KG, Kimes TM, Rosales AG, Hauske SJ. Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs without type 2 diabetes. BMC Nephrol. 2020;21(1):167.","journal-title":"BMC Nephrol"},{"issue":"13","key":"669_CR26","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","volume":"330","author":"Writing Group for the CKD Prognosis Consortium","year":"2023","unstructured":"Writing Group for the CKD Prognosis Consortium. Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis. JAMA. 2023;330(13):1266\u201377.","journal-title":"JAMA"},{"key":"669_CR27","unstructured":"Centers for Disease Control and Prevention. CDC Surveillance System: SGLT2i use among Patients with CKD and Diabetes. 2020 2024\/09\/11; Available from: https:\/\/nccd.cdc.gov\/CKD\/detail.aspx?Qnum=Q719"},{"issue":"10","key":"669_CR28","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2215\/CJN.14901219","volume":"15","author":"A Levin","year":"2020","unstructured":"Levin A, Perkovic V, Wheeler DC, Hantel S, George JT, von Eynatten M, et al. Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: post hoc analysis of a randomized, double-blind, placebo-controlled, multinational trial. Clin J Am Soc Nephrol. 2020;15(10):1433\u201344.","journal-title":"Clin J Am Soc Nephrol"},{"key":"669_CR29","unstructured":"GoodRx. How much does dialysis cost? 2025; Available from: https:\/\/www.goodrx.com\/health-topic\/kidneys\/dialysis-cost"},{"key":"669_CR30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.12659\/AOT.914661","volume":"24","author":"A \u0141abu\u015b","year":"2019","unstructured":"\u0141abu\u015b A, Niemczyk M, Czy\u017cewski \u0141, Fliszkiewicz M, Kulesza A, Mucha K, et al. Costs of long-term post-transplantation care in kidney transplant recipients. Ann Transplant. 2019;24:252\u20139.","journal-title":"Ann Transplant"},{"key":"669_CR31","unstructured":"Bentley T, Ortner N. 2020 U.S. organ and tissue transplants: cost estimates, discussion, and emerging issues. https:\/\/www.milliman.com\/en\/Insight\/2020-us-organ-and-tissue-transplants2020."},{"key":"669_CR32","unstructured":"Cost Digest. Cost of SGLT2 inhibitors: price ranges and budget guide 2026. 2026; Available from: https:\/\/costdigest.org\/cost-sglt2-inhibitors-price-ranges-budget\/"},{"key":"669_CR33","unstructured":"Bharadwaj S. Aurobindo Pharma receives USFDA nod for two dapagliflozin tablets. 2026; Available from: https:\/\/timesofindia.indiatimes.com\/business\/india-business\/aurobindo-pharma-receives-usfda-nod-for-two-dapagliflozin-tablets\/articleshow\/130093345.cms"},{"issue":"8","key":"669_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.2530","volume":"5","author":"M Serra-Burriel","year":"2024","unstructured":"Serra-Burriel M, Martin-Bassols N, Per\u00e9nyi G, Vokinger KN. Drug prices after patent expirations in high-income countries and implications for cost-effectiveness analyses. JAMA Health Forum. 2024;5(8):e242530.","journal-title":"JAMA Health Forum."},{"key":"669_CR35","unstructured":"Drugs.com. Generic Drugs - Availability and Patent Status. 2026; Available from: https:\/\/www.drugs.com\/availability\/"},{"issue":"9","key":"669_CR36","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","volume":"6","author":"V Perkovic","year":"2018","unstructured":"Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691\u2013704.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"669_CR37","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"669_CR38","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"6","key":"669_CR39","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","volume":"64","author":"DZI Cherney","year":"2021","unstructured":"Cherney DZI, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, et al. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia. 2021;64(6):1256\u201367.","journal-title":"Diabetologia"},{"issue":"1","key":"669_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1053\/j.ajkd.2020.06.018","volume":"77","author":"BL Neuen","year":"2021","unstructured":"Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, et al. Relative and absolute risk reductions in cardiovascular and kidney outcomes with canagliflozin across KDIGO risk categories: findings from the CANVAS program. Am J Kidney Dis. 2021;77(1):23\u201334 (e1).","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"669_CR41","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851\u201360.","journal-title":"N Engl J Med"},{"key":"669_CR42","unstructured":"Centers for Medicare & Medicaid Services (CMS). Clinical Laboratory Fee Schedule: 2026 Annual Update. 2026; Available from: https:\/\/www.cms.gov\/files\/document\/mm14312-clinical-laboratory-fee-schedule-2026-annual-update.pdf"},{"issue":"10","key":"669_CR43","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.2337\/dc14-1296","volume":"37","author":"KR Tuttle","year":"2014","unstructured":"Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864\u201383.","journal-title":"Diabetes Care"},{"issue":"10","key":"669_CR44","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"},{"key":"669_CR45","unstructured":"U.S. Bureau of Labor Statistics. Consumer price index for all urban consumers: medical care in U.S. City average [CPIMEDSL]. 2026. Available from: https:\/\/fred.stlouisfed.org\/series\/CPIMEDSL"},{"issue":"5","key":"669_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217487","volume":"14","author":"J Thornton Snider","year":"2019","unstructured":"Thornton Snider J, Sullivan J, van Eijndhoven E, Hansen MK, Bellosillo N, Neslusan C, et al. Lifetime benefits of early detection and treatment of diabetic kidney disease. PLoS ONE. 2019;14(5):e0217487.","journal-title":"PLoS ONE"},{"issue":"1","key":"669_CR47","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1080\/13696998.2021.1960714","volume":"24","author":"M Datar","year":"2021","unstructured":"Datar M, Burchenal W, Donovan MJ, Coca SG, Wang E, Goss TF. Payer budget impact of an artificial intelligence in vitro diagnostic to modify diabetic kidney disease progression. J Med Econ. 2021;24(1):972\u201382.","journal-title":"J Med Econ"},{"issue":"8","key":"669_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271740","volume":"17","author":"L Fusfeld","year":"2022","unstructured":"Fusfeld L, Murphy JT, Yoon Y, Kam LY, Peters KE, Lin Tan P, et al. Evaluation of the clinical utility of the PromarkerD in-vitro test in predicting diabetic kidney disease and rapid renal decline through a conjoint analysis. PLoS ONE. 2022;17(8):e0271740.","journal-title":"PLoS ONE"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00669-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00669-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00669-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:14:11Z","timestamp":1789992851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-026-00669-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["669"],"URL":"https:\/\/doi.org\/10.1007\/s41669-026-00669-4","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Proteomics International is a beneficiary of patent PCT\/AU2011\/001212 that relates to biomarkers used in the PromarkerD in vitro test described in this manuscript. KEP and RJL are named inventors of this patent. GCF, IAJ, KEP, LKC, JSG, PLT, and RJL are past or present employees and shareholders of Proteomics International. MS is a member of the Clinical Advisory Board for Proteomics International. The authors acknowledge that commercial adoption of PromarkerD could provide financial benefit to Proteomics International and affiliated individuals.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors certify that they meet the ICMJE criteria for authorship. Conceptualization of study: GCF, KEP, LKC, JSG, PLT, RJL; input data curation: IAJ, KEP, LKC, PLT; model development and programming: GCF, IAJ, LKC, JSG; formal analysis and interpretation: GCF, IAJ, KEP, LKC, JSG, PLT, MS; validation: IAJ, KEP, LKC, JSG, PLT; manuscript preparation (original draft): GCF, IAJ; manuscript preparation (review and editing): GCF, KEP, LKC, JSG, MS; supervision: KEP, JSG, PLT, RJL.","order":2,"name":"Ethics","label":"Authorship Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for this study was provided by Proteomics International (URL:\n                      \n                      ). Proteomics International employs\/employed GCF, IAJ, KEP, LKC, JSG, PLT and RJL, who had a role in influencing study design, the decision to publish, and the preparation of the manuscript.","order":3,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study were generated by and are the property of Proteomics International. These data contain proprietary information that is not publicly available owing to commercial restrictions. Summary data and model assumptions derived from publicly available sources are included in the article and its Supplementary Material. Further details of the budget impact model may be made available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study used published literature and modelling data and did not involve human participants or identifiable patient data.","order":5,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Consent for Publication (from Patients\/Participants)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The budget impact model was developed in Microsoft Excel and contains proprietary components. Additional details may be available from the corresponding author upon reasonable request.","order":8,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}